Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Case 17% Improvement Relative Risk HCQ for COVID-19  Desbois et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 199 patients in France Study underpowered to detect differences c19hcq.org Desbois et al., Research Square, July 2020 Favors HCQ Favors control

Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with sarcoidosis

Desbois et al., Research Square, doi:10.21203/rs.3.rs-41653/v1
Jul 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Retrospective 199 sarcoidosis patients showing non-statistically significant HCQ RR 0.83, p=1.0.
risk of case, 16.9% lower, RR 0.83, p = 1.00, treatment 3 of 27 (11.1%), control 23 of 172 (13.4%), NNT 44.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Desbois et al., 20 Jul 2020, retrospective, France, preprint, mean age 58.8, 13 authors.
This PaperHCQAll
Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with sarcoidosis
Anne-Claire Desbois, Cindy Marques, Leila Lefèvre, Serge Barmo, Camille Lorenzo, Mathilde Leclercq, Gaëlle Leroux, Chloé Comarmond, Catherine Chapelon, Fanny Domont, Mathieu Vautier, David Saadoun, Patrice Cacoub
doi:10.21203/rs.3.rs-41653/v1
Objective: To investigate the prevalence, clinical features and outcomes of coronavirus disease 2019 (COVID-19) among sarcoidosis patients. Methods: We retrospectively collected features of COVID-19 in a cohort of patients with sarcoidosis followed in a single tertiary university hospital. Results: Among 199 sarcoidosis patients [mean age 58.8 (±14) years, 86 (43.2%) men], 26 (13%) were diagnosed with , probable (n=12) and possible (n=7) ]. Twenty-four out of 26 patients (92%) had at least one comorbidity, and 11/26 (42%) had two or more comorbidities. Demographic and clinical features of COVID-19 positive patients were similar to those of COVID-19 negative patients. The administration of hydroxychloroquine or immunosuppressant was not associated with the occurrence or the severity of COVID-19. Four out of 26 (15.4%) COVID-19 positive patients required admission to hospital and two of them died. Hospitalized patients [mean age of 61 (±11.5) years] were receiving higher doses of long term treatment with corticosteroids than nonhospitalized patients; 4/4 had pulmonary and 2/4 cardiac involvement of sarcoidosis, and all one or more comorbidity. Conclusion: The prevalence of COVID-19 in sarcoidosis is slightly higher to that of the general population. Almost half of the COVID-19 positive patients have two or more comorbidities and about 15% present a severe course.
Declarations Ethics approval and consent to participate: The study was approved by our institutional ethics review board "Ethics committee of research in Sorbonne University". All patients gave informed consent. Consent for publication: Not applicable. Competing interests: The authors declare that they have no competing interests. Authors' contributions: ACD contributed to the conception and design of the work. ACD and CM wrote the manuscript. ACD, CM, LL, SB, CL, ML, GL, CC, CCA, FD, MV and DS collected the data. CM have drafted the work PC supervised the findings of this work. All authors approved the final manuscript.
References
Alijotas-Reig, Esteve-Valverde, Belizna, Selva-O'callaghan, Pardos-Gea et al., Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review, Autoimmun Rev
Boulware, Pullen, Bangdiwala, Pastick, Lofgren et al., A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19, N Engl J Med
Brenner, Ungaro, Gearry, Kaplan, Kissous-Hunt et al., Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry, Gastroenterology
Buckner, Mcculloch, Atluri, Blain, Mcguffin et al., Clinical Features and Outcomes of 105 Hospitalized patients with COVID-19 in Seattle, Washington, Clin Infect Dis
Chakladar, Shende, Li, Rajasekaran, Chang et al., Smoking-Mediated Upregulation of the Androgen Pathway Leads to Increased SARS-CoV-2 Susceptibility
Grasselli, Zangrillo, Zanella, Antonelli, Cabrini et al., Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, JAMA
Haberman, Axelrad, Chen, Castillo, Yan et al., Covid-19 in Immune-Mediated Inflammatory Diseases -Case Series from New York, N Engl J Med
Haberman, Axelrad, Chen, Castillo, Yan et al., Covid-19 in Immune-Mediated Inflammatory Diseases -Case Series from New York, N Engl J Med
Hunninghake, Costabel, Ando, Baughman, Cordier et al., ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders, Sarcoidosis Vasc Diffuse Lung Dis
Llanos, Hamzeh, Sarcoidosis, Med Clin North Am
Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area, JAMA
Salje, Kiem, Lefrancq, Courtejoie, Bosetti et al., Estimating the burden of SARS-CoV-2 in France, Science
Silva, Boyd, Wallwork, Hsu, Fu et al., Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US "hot spot, Ann Rheum Dis
Song, Hong, Lim, Koh, Kim, Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome, Eur Respir J
Toniati, Piva, Cattalini, Garrafa, Regola et al., Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy, Autoimmun Rev
Wang, Hu, Hu, Zhu, Liu et al., Clinical Characteristics of 138
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
Zhu, She, Cheng, Qin, Zhang et al., Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes, Cell Metab
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit